Patents by Inventor Tracy Ann Perry

Tracy Ann Perry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190070215
    Abstract: Methods and devices for use in reducing the appearance of dimpled skin or other undesirable appearance of skin in a cellulitic region of a patient are provided. The methods include the steps of disrupting fibrous septae located beneath the skin of a cellulitic region and introducing a composition beneath the skin, the composition being effective to reduce or prevent regrowth of the fibrous septae.
    Type: Application
    Filed: November 5, 2018
    Publication date: March 7, 2019
    Inventors: Tracy Ann Perry, Rui Avelar, Justin Schwab, Zachary Dominguez, Edwin Kayda
  • Patent number: 10117892
    Abstract: Methods and devices for use in reducing the appearance of dimpled skin or other undesirable appearance of skin in a cellulitic region of a patient are provided. The methods include the steps of disrupting fibrous septae located beneath the skin of a cellulitic region and introducing a composition beneath the skin, the composition being effective to reduce or prevent regrowth of the fibrous septae.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: November 6, 2018
    Assignee: Allergan, Inc.
    Inventors: Tracy Ann Perry, Rui Avelar, Justin Schwab, Zachary Dominguez, Edwin Kayda
  • Publication number: 20150064165
    Abstract: Methods and devices for use in reducing the appearance of dimpled skin or other undesirable appearance of skin in a cellulitic region of a patient are provided. The methods include the steps of disrupting fibrous septae located beneath the skin of a cellulitic region and introducing a composition beneath the skin, the composition being effective to reduce or prevent regrowth of the fibrous septae.
    Type: Application
    Filed: August 29, 2014
    Publication date: March 5, 2015
    Inventors: Tracy Ann Perry, Rui Avelar, Justin Schwab, Zackary Dominguez, Edwin Kayda
  • Publication number: 20120329715
    Abstract: The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.
    Type: Application
    Filed: August 24, 2012
    Publication date: December 27, 2012
    Applicant: The Gov. of the US, as represented by the Secretary, Dept. of Health & Human Services
    Inventors: Nigel Greig, Josephine Egan, Maire Doyle, Harold Holloway, Tracy Ann Perry
  • Patent number: 8278272
    Abstract: The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: October 2, 2012
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Nigel Greig, Josephine Egan, Maire Doyle, Harold Holloway, Tracy Ann Perry
  • Publication number: 20090253625
    Abstract: The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.
    Type: Application
    Filed: December 18, 2008
    Publication date: October 8, 2009
    Inventors: Nigel Greig, Josephine Egan, Maire Doyle, Harold Holloway, Tracy Ann Perry
  • Patent number: 7576050
    Abstract: The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.
    Type: Grant
    Filed: July 30, 2002
    Date of Patent: August 18, 2009
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Nigel Greig, Josephine Egan, Maire Doyle, Harold Holloway, Tracy Ann Perry